Morglin-M Tablet ER
Morglin-M Tablet ER
Metformin (500mg) + Teneligliptin (20mg)
Cheaper alternative availability
Already at the Best Price
This medicine doesn't have a cheaper alternative with the same composition. Our health advisors can help you find other savings options based on your prescription.
About This Medicine
Product description & overview
Morglin-M Tablet ER is a once-daily, extended-release combination product containing metformin 500mg and teneligliptin 20mg, indicated for the treatment of type 2 diabetes mellitus. The tablet is designed to provide consistent and controlled release of the active ingredients over a 24-hour period. Metformin, an biguanide, improves insulin sensitivity and reduces glucose production in the liver, while teneligliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, increases insulin secretion and reduces glucagon levels. The combination of metformin and teneligliptin provides a synergistic effect in improving glycemic control, reducing fasting plasma glucose levels, and minimizing the risk of hypoglycemia. Morglin-M Tablet ER is suitable for patients who require a combination of metformin and a DPP-4 inhibitor for the management of type 2 diabetes. It is available in a once-daily, easy-to-administer tablet form, with a low risk of gastrointestinal side effects. The recommended starting dose is one tablet once daily, with adjustments as needed to achieve the target glycemic control.
Active composition
Metformin 500 mg
+1 more active ingredient
About Metformin
Metformin is an oral antihyperglycemic agent used to manage type 2 diabetes mellitus. It works by decreasing glucose production in the liver and improving insulin sensitivity. Metformin is effective in controlling blood sugar levels and preventing diabetes-related complications. In summary, Metformin is vital for managing type 2 diabetes.
How It Works
Metformin reduces hepatic glucose production and enhances peripheral insulin sensitivity, lowering blood glucose levels.
All Active Ingredients
Teneligliptin
Teneligliptin inhibits DPP-4, increasing incretin levels and enhancing insulin secretion.
Dosage & How to Use
Dosage information not available. Please consult your doctor or pharmacist.
Safety Advice
Important precautions
Side Effect Occurrence
Based on clinical trials and patient reports.
Overall Tolerance
Most patients tolerate well
Common Side Effects
Safety Advice
Alcohol
Morglin-M Tablet ER may be unsafe to use during pregnancy. Although there are limited studies in humans, animal studies have shown harmful effects on the developing baby. Your doctor will weigh the benefits and any potential risks before prescribing it to you. Please consult your doctor.
High Risk
Pregnancy
Morglin-M Tablet ER is probably unsafe to use during breastfeeding. Limited human data suggests that the drug may pass into the breastmilk and harm the baby.
Medical Advice
Driving
Morglin-M Tablet ER should be used with caution in patients with kidney disease. Dose adjustment of Morglin-M Tablet ER may be needed. Please consult your doctor. Use of Morglin-M Tablet ER is, however, not recommended in patients with severe kidney disease. Regular monitoring of kidney function test is advisable while you are taking this medicine.
Exercise Caution
Breastfeeding
It is not known whether Morglin-M Tablet ER alters the ability to drive. Do not drive if you experience any symptoms that affect your ability to concentrate and react.
Consult Doctor
Kidney
Morglin-M Tablet ER is probably unsafe to use in patients with liver disease and should be avoided. Please consult your doctor.
Regular Checkup
Customer Reviews
0 reviews for Morglin-M Tablet ER
